Antifungal treatments for yeast infection
Pro Research Analysisby 
Searched over 200M research papers
Conventional Antifungal Treatments for Yeast Infections
The main classes of antifungal drugs used to treat yeast infections are azoles, polyenes, echinocandins, allylamines, and nucleoside analogues. Azoles (like fluconazole) are commonly used due to their effectiveness and low toxicity, but resistance is increasing, especially among non-albicans Candida species and Malassezia yeasts. Polyenes (such as amphotericin B) and echinocandins are also used, particularly for more severe or resistant infections. Topical antifungals are often used for skin and nail infections, while oral or intravenous antifungals are reserved for systemic or severe cases. However, treatment failures and recurrence are common, often due to resistance or incomplete treatment courses 279.
Antifungal Drug Resistance and the Need for Alternatives
Resistance to conventional antifungals, especially azoles, is a growing problem. Some yeasts, like Candida krusei and Candida auris, have intrinsic or rapidly acquired resistance to multiple drug classes, making infections harder to treat. Mechanisms of resistance include changes in drug targets, reduced drug uptake, and the development of bypass pathways. This has led to a search for new drugs and alternative therapies, as the current antifungal arsenal is limited and drug development is challenging due to the similarities between fungal and human cells 569.
Novel and Investigational Antifungal Agents
Several new antifungal agents are in clinical development, including fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole, VT-1598, PC945, and olorofim. These drugs offer new mechanisms of action, improved safety, and better pharmacokinetic profiles, which may help overcome current limitations and resistance issues. Some of these agents are first-in-class, while others are improvements on existing drug classes 45.
Natural and Plant-Based Antifungal Treatments
Natural substances, such as plant extracts and essential oils, are being explored as alternative treatments for yeast infections. Compounds like berberine, carnosic acid, and propolis have shown antifungal activity, including against drug-resistant strains and biofilm-forming yeasts. These natural agents can disrupt fungal cell membranes and induce cell death, sometimes enhancing the effects of conventional drugs when used in combination or sequentially. However, challenges like poor bioavailability and delivery need to be addressed, and incorporating these agents into films or hydrogels may improve their effectiveness for skin infections 138.
Antifungal Peptides as Emerging Therapies
Antifungal peptides (AFPs) are another promising alternative. These naturally occurring or synthetic peptides have broad-spectrum activity, rapid killing action, and a low risk of resistance development. Advances in peptide design are improving their stability and bioavailability, but further research is needed to optimize delivery and safety before they can be widely used in clinical practice .
Conclusion
Yeast infections are commonly treated with azoles, polyenes, and echinocandins, but rising resistance and treatment failures highlight the need for new options. Novel antifungal drugs, natural compounds, and antifungal peptides are promising alternatives under investigation. Continued research and development are essential to address resistance and improve outcomes for patients with yeast infections 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic